Introduction
Drug-drug interactions derived from metabolizing enzymes potentially occur on the occasions of drug combinations, and potentially impact drug efficacy and safety. It's known that the human cytochrome P450 3A (CYP3A) subfamily is involved in the metabolism of more than 50% of marketed drugs. Assessment of drug-drug interaction related to CYP3A is therefore a very important aspect during the drug discovery and development.
Rifampicin, a well-known strong CYP3A inducer in vivo, increased the plasma concentrations of endogenous 4β-hydroxycholesterol to the similar extents as the CYP3A4 activity index (based on the probe drug quinine) indicated in a trial enrolling 24 healthy volunteers (Kanebratt et al., 2008) . The average plasma concentration of 4β-hydroxycholesterol in healthy volunteers was approximately 30 ng/mL, while the average level increased to over 200 ng/mL in the patients treated with the antiepileptics (carbamazepine, phenytoin or phenobarbital) that were thought to be strong CYP3A inducers similar as rifampicin (Bodin et al., 2001) .
Research in vitro
showed that biotransformation of cholesterol to 4β-hydroxycholesterol is specifically catalyzed by human CYP3A4/5 (Bodin et al., 2001) . 4β-Hydroxycholesterol is replacing probe drugs to be an indicator of CYP3A activity in humans Diczfalusy et al., 2011; Josephson et al., 2008; Lütjohann et al., 2009) , which makes studies simpler and safer by eliminating the use of probe drugs especially in the patients who are at high risk of CYP3A involved drug-drug interactions during their therapies.
Nonhuman primates, including cynomolgus (Macaca fascicularis) and rhesus (Macaca mulatta) monkeys, have been used in pharmaceutical development as preclinical models because they are physiologically and anatomically similar to humans. Cynomolgus monkey CYP3A8 is 93% identical at the amino acid level to human CYP3A4 (Carr et al., 2006) , and cynomolgus monkey pregnane X receptor (PXR) was highly homologous to human PXR (96%) (Kim et al., 2010 showing comparable increases of RNA expression and enzyme activity between cynomolgus monkey CYP3A8 and human CYP3A4 (Kim et al., 2010) . In addition, both human and cynomolgus monkey have CYP3A5 (Iwasaki and Uno, 2009 ).
Therefore, cynomolgus monkey could potentially be a predictive animal model for human CYP3A4/5 induction.
Based on the evidence of cynomolgus monkey as an animal model for human prediction and 4β-hydroxycholesterol as the biomarker of human CYP3A4/5 activity, the present study is demonstrating that 4β-hydroxycholesterol is also an endogenous indicator of the cynomolgus monkey CYP3A8/5 activity, which may assist to assess the CYP3A induction potential of drug candidates at the preclinical stage.
Materials and Methods

Chemicals and reagents
Rifampicin (purity 97%) and midazolam injection (5 mg/mL) were purchased from 
Animals
Male and female cynomolgus (Macaca fascicularis) monkeys (2.7 -5.5 kg; 3.3 -5.3 years old) were purposely bred in Hainan, China. Thirty-one male and 15 female cynomolgus monkeys were investigated for the basal concentrations of cholesterol and 4β-hydroxycholesterol in serum. The animals were fed standard monkey feed commercially provided by Beijing Keao Xieli Co., Ltd. (Beijing, China).
CYP3A induction by rifampicin treatment in monkeys
Five male animals were orally administered 2 mg/kg midazolam (1 mg/mL in 0.9% were conducted prior to each rifampicin dosing on Days 2, 3, 5, 8, 11, 14 and 15, and on Days 17, 19, 22, 25, 29, 32 and 36 .
In vitro incubation in recombinant cynomolgus monkey CYPs
To identify CYP(s) responsible for the biotransformation of cholesterol to 4β-hydroxycholesterol, 100 μ mol/L of cholesterol was incubated with 200 pmol/mL of recombinant cynomolgus CYP2C43, CYP2C75, CYP2C76, CYP2C20, CYP3A8
or CYP3A5 (purchased from Cypex Ltd., Scotland, UK) for 60 minutes at 37 o C, and 4β-hydroxycholesterol was determined using an LC-MS/MS method described below.
For Km and Vmax estimation, 10, 25, 50, 100, 200, 300 or 500 μ mol/L of cholesterol was incubated with 100 pmol/mL of CYP3A8 or CYP3A5 for 60 minutes at 37 o C.
4β-Hydroxycholesterol was determined, and Km and Vmax were calculated using the software WinNonlin (version 5.2.1, Pharsight Corporation, California, USA). The incubation system also contained 4 mmol/L MgCl 2 and 1 mmol/L NADPH.
LC-MS/MS analysis of 4β-hydroxycholesterol, cholesterol and midazolam
The assay for 4β-hydroxycholesterol and cholesterol in monkey serum was adapted from a previously reported method for human plasma (Xu et al., 2013) . Briefly, serum sample was mixed with internal standard (4β-hydroxycholesterol-d7 and cholesterol-d7) and 1 mol/L potassium hydroxide, and incubated at 37 o C for 1 hour. 
Pharmacokinetic analysis
The pharmacokinetic (PK) parameters were derived from the serum concentration versus time profile in each animal, using the noncompartmental analysis of WinNonlin (Version 5.2.1, Pharsight). The concentration ratios of 4β-hydroxycholesterol to cholesterol were also used for a limited PK analysis to obtain the maximum ratio (Ratio max ), the basal ratio prior to rifampicin dosing (Ratio base ) and the terminal half-life (t 1/2, ratio ) .
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Results and Discussion
LC-MS/MS analysis of 4β-hydroxycholesterol, cholesterol and midazolam
The assay for 4β-hydroxycholesterol and cholesterol in monkey serum was adapted from a validated LC-MS/MS method for human plasma that exhibited good chromatographic separations between 4β-hydroxycholesterol and other isobaric oxysterols 24S-, 25-, 27-, 7α-, 7β-hydroxycholesterol (Xu et al., 2013) . Especially, an adequate separation from the closest 4α-hydroxycholesterol was demonstrated. Fig. 1 shows the chromatograms of 4α-hydroxycholesterol, 4β-hydroxycholesterol and cholesterol in a monkey serum sample prior to rifampicin treatment. For the determination of 4β-hydroxycholesterol and cholesterol concentrations in serum, the standard curves were fit with a linear regression, and the calibration range was from 5 to 500 ng/mL for 4β-hydroxycholesterol and from 20 to 2000 µg/mL for cholesterol.
For 4β-hydroxycholesterol, the quality control (QC) samples in the analysis run exhibited the bias of -13.3%, -4.0% and -2.8%, respectively, at the levels of 15, 200
and 400 ng/mL, and the CV% (coefficient of variance) of 0.7%, 6.8% and 4.8%, respectively. For cholesterol at the QC levels of 60, 800 and 1600 µg/mL, the bias values were -5.0%, -1.0% and -5.0%, respectively, and the CV% values were 11.9%, 6.6% and 5.7%, respectively.
For the determination of midazolam concentrations in serum, the standard curves were fit with a linear regression, and the calibration range was from 0.1 to 100 ng/mL.
The QC samples in the analysis run exhibited the bias of -3.3%, 2.3% and -8.3%, respectively, for 0.3, 30 and 75 ng/mL, and the CV% of 7.5%, 4.1% and 4.0%,
respectively.
Basal levels of 4β-hydroxycholesterol and cholesterol in cynomolgus monkeys
The basal levels of 4β-hydroxycholesterol and cholesterol were determined in 31 male and 15 female cynomolgus monkeys (Table 1) ) for the male and female animals.
Midazolam exposure and 4β-hydroxycholesterol level after rifampicin treatment in cynomolgus monkeys
After multiple oral dosing of 15 mg/kg/day rifampicin (once daily for 14 consecutive days) in 5 male cynomolgus monkeys, the midazolam exposure in serum markedly decreased by 94.5% from 110±34.3 to 5.84±1.79 (mean±SD) hr×ng/mL for AUC 0-∞ and by 94.1% from 58.4±24.3 to 3.42±1.18 ng/mL for C max at the single oral dose level of 2 mg/kg (Table 2) cholesterol in serum was 0.695±0.158 mg/mL, and during the 14-day rifampicin treatment the average concentrations ranged from 0.516 to 0.628 mg/mL. The elevated 4β-hydroxycholesterol/cholesterol level returned to the base line with the half-life of 15.3±4.3 day after the rifampicin treatment termination. In terms of 4β-hydroxycholesterol, the t 1/2 was 12.7±5.0 day. The data are listed in Table 3 . As shown by Fig. 2 , the normalization of 4β-hydroxycholesterol concentration by the respective cholesterol level minimized the variability of the elevated 4β-hydroxycholesterol levels in monkeys.
It has reported that rifampicin at 15 mg/kg/day in the cynomolgus monkey provided the C max value comparable to that from the treatment of 600 mg/day in the human (Kim, et al., 2010) . The same dosing regimen of rifampicin and midazolam was applied to the present study, except that the dosing duration was extended from 7 days to 14 days. The change of midazolam exposure observed in this study was similar to the reported results of 92% in cynomolgus monkeys (15 mg/kg/day rifampicin; once daily for 7 days) and 94% in human subjects (600 mg/day rifampicin; once daily for 5 days) (Kim, et al., 2010) . In line with the decrease of midazolam exposure, 4β-hydroxycholesterol concentration in serum increased 4-fold in the monkey, which was very similar to the observation following the induction by rifampicin in healthy volunteers (500 mg/day; once daily for 14 days) . Moreover, the terminal half-life of 4β-hydroxycholesterol was 13 days (for 4β-hydroxycholesterol/cholesterol, 15 days) in cynomolgus monkeys, which was close to the 4β-hydroxycholesterol half-life of 17 days observed in humans.
It was observed that the fold of the change of 4β-hydroxycholesterol level was not as drastic as that of midazolam exposure in this study. In response to the rifampicin treatment in the monkey, there was a 10-fold change for midazolam exposure but only 4-fold for 4β-hydroxycholesterol level. Similar observation was reported for efavirenz in HIV-1 positive patients. Following oral repeated administrations of efavirenz (600 mg/day, once daily for at least 21 days) to patients, the median midazolam index (plasma concentration ratio of 1-hydroxymidazolam/midazolam) increased 5-fold compared with the placebo group (Fellay J, et al., 2005) , whereas the median 4β-hydroxycholesterol level (after the treatment of 600 mg/day for 28 days) in plasma increased only 2-fold (Josephson F, et al., 2008) .
The present study also indicated that the endogenous 4β-hydroxycholesterol had a long elimination half-life of more than 10 days after its level was elevated. Due to the long half-life, the 4β-hydroxycholesterol level may appear unchangeable for a rapid decline of CYP3A activity such as an inhibition effect caused by a short exposure to a reversible inhibitor. It was reported even if the exposure to CYP3A inhibitors was maintained for a few days, the endogenous 4β-hydroxycholesterol levels did not decease as markedly as it increased in induction studies. Repeated oral administrations of ketoconazole at 400 mg/day (once daily for 4 days) resulted in a decrease of only 17% in the 4β-hydroxycholesterol level in healthy human subjects (Goodenough AK, et al., 2011) , and the oral dosing of itraconazole (once daily for 1 week at 400 mg/day) led to a decrease of 25% in patients with onychomycosis (Lütjohann D, et al., 2009) .
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In vitro CYP identification and kinetics estimation in recombinant CYPs
No 4β-hydroxycholesterol was detected after cholesterol was incubated with recombinant cynomolgus CYP2C20, CYP2C43, CYP2C75 or CYP2C76, but with CYP3A8 and CYP3A5. The values of Km and Vmax were estimated to be 204 μ mol/L and 0.600 pg/pmol/min for cynomolgus CYP3A8, and 104 μ mol/L and 0.310 pg/pmol/min for cynomolgus CYP3A5. The Km values for cynomolgus monkey CYP3A8 and CYP3A5 estimated in this study were higher than reported for human CYP3A4, although similar Vmax was observed (Shinkyo and Guengerich, 2011) .
In summary, this study showed that cynomolgus monkey and the human exhibited similar changes in midazolam exposure and in 4β-hydroxycholesterol concentration after rifampicin treatment at an exposure comparable dose level, which echoed the reported high homology between cynomolgus monkey CYP3A8 and human CYP3A4.
The formation of 4β-hydroxycholesterol from cholesterol was specifically catalyzed by CYP3A8/5 in cynomolgus monkeys. 4β-Hydroxycholesterol is not as sensitive as the classical CYP3A probe midazolam, and may be more beneficial for induction studies than for inhibition investigations. As an endogenous biomarker, 4β-hydroxycholesterol can be used to identify potential strong CYP3A inducers in cynomolgus monkeys, which may help to evaluate drug-drug interaction potential of drug candidates in preclinical settings. 
